Plasma prolactin in juvenile diabetics. 24-h studies with somatostatin. 1978

K F Hanssen, and S E Christensen, and A P Hansen, and K Lundbaek, and P A Torjesen, and J Weeke

In normal subjects during 24-hours saline infusion, plasma prolactin showed a number of small rises during day and night. The mean night-time level was significantly higher than the day-time level (8.2 +/- 0.6 ng/ml as against 4.7 +/- 0.5 ng/ml). In 12 insulin-dependent diabetics the 24 h plasma prolactin pattern was identical to that found in normals. Somatostatin infusion (4 mg/24 h in normals; 2--6 mg/24 h in diabetics) had no effect on the 24 h plasma prolactin pattern in either normals or in diabetics.

UI MeSH Term Description Entries
D008297 Male Males
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D002940 Circadian Rhythm The regular recurrence, in cycles of about 24 hours, of biological processes or activities, such as sensitivity to drugs or environmental and physiological stimuli. Diurnal Rhythm,Nyctohemeral Rhythm,Twenty-Four Hour Rhythm,Nycthemeral Rhythm,Circadian Rhythms,Diurnal Rhythms,Nycthemeral Rhythms,Nyctohemeral Rhythms,Rhythm, Circadian,Rhythm, Diurnal,Rhythm, Nycthemeral,Rhythm, Nyctohemeral,Rhythm, Twenty-Four Hour,Rhythms, Circadian,Rhythms, Diurnal,Rhythms, Nycthemeral,Rhythms, Nyctohemeral,Rhythms, Twenty-Four Hour,Twenty Four Hour Rhythm,Twenty-Four Hour Rhythms
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone

Related Publications

K F Hanssen, and S E Christensen, and A P Hansen, and K Lundbaek, and P A Torjesen, and J Weeke
March 1978, Diabetes,
K F Hanssen, and S E Christensen, and A P Hansen, and K Lundbaek, and P A Torjesen, and J Weeke
May 1971, Scandinavian journal of clinical and laboratory investigation,
K F Hanssen, and S E Christensen, and A P Hansen, and K Lundbaek, and P A Torjesen, and J Weeke
September 1978, Metabolism: clinical and experimental,
K F Hanssen, and S E Christensen, and A P Hansen, and K Lundbaek, and P A Torjesen, and J Weeke
June 1974, Harefuah,
K F Hanssen, and S E Christensen, and A P Hansen, and K Lundbaek, and P A Torjesen, and J Weeke
January 1985, Minerva endocrinologica,
K F Hanssen, and S E Christensen, and A P Hansen, and K Lundbaek, and P A Torjesen, and J Weeke
January 1981, Acta medica Scandinavica,
K F Hanssen, and S E Christensen, and A P Hansen, and K Lundbaek, and P A Torjesen, and J Weeke
January 2004, Journal of psychiatric research,
K F Hanssen, and S E Christensen, and A P Hansen, and K Lundbaek, and P A Torjesen, and J Weeke
March 1980, Canadian journal of physiology and pharmacology,
K F Hanssen, and S E Christensen, and A P Hansen, and K Lundbaek, and P A Torjesen, and J Weeke
July 1964, The Journal of the Association of Physicians of India,
K F Hanssen, and S E Christensen, and A P Hansen, and K Lundbaek, and P A Torjesen, and J Weeke
May 1969, British medical journal,
Copied contents to your clipboard!